Enrollment completed for RE-DUAL PCI™ study of 2,700 atrial fibrillation patients

(WHITECOAT STRATEGIES, LLC) The Baim Institute announces that patient enrollment into the international Phase IIIb RE-DUAL PCI™ study is complete. The study evaluates the safety and efficacy of dabigatran etexilate (marketed as Pradaxa®) in atrial fibrillation patients undergoing a percutaneous coronary intervention with stent placement. This is the first time that two dosages of a non-vitamin K antagonist oral anticoagulant already approved for stroke prevention in AF are evaluated in a dual versus triple antithrombotic regimen after PCI.